Abstract 1817: Differential expression of long non-coding RNA in colon adenocarcinoma RNA-sequence data set
Authors: Stephen J. O'Brien, Theodore Kalbfleisch, Sudhir Srivastava, Shesh Rai, Susan Galandiuk
Journal: Cancer Research (2019)

Abstract Introduction: Colon cancer is the fourth most common cancer in the United States and the third leading cause of cancer-related death. High throughput genomic sequencing has led to a number of significant advances in tumor biology and in identifying novel signaling molecules such as long non-coding RNA (lncRNA). The aim of this study was to identify differentially expressed lncRNA in colon cancer from a large RNA-sequencing (RNA-seq) data set. Methods: The raw RNA-seq files of 398 patients with colon cancer were downloaded from The Cancer Genome Atlas (TCGA). Sequencing files were aligned using STAR (Spliced Transcripts Alignment to a Reference) to the most recent genome annotation. Using a subset of patients with paired colon cancer and normal colon epithelium RNA-seq data (n=40), an exploratory binomial regression model was used to calculate differential RNA expression. The most differentially expressed lncRNA were identified from the exploratory analysis and verified by comparing the larger colon cancer RNA-seq data set (n=358) with the normal colon epithelium RNA-seq data set (n=40). Results: 33,514 genes were identified from the comparative analysis, and using differential expression cut off values of &amp;gt; +1.5 or &amp;lt; -1.5 log fold change and a false discovery rate of &amp;lt;0.05; 543 were upregulated and 1822 were downregulated. Within this dysregulated group, 60 lncRNAs were identified. Using the larger data set (n=358 vs n=40), 41/60 lncRNA remained differentially expressed, of which 15 were downregulated and 26 were upregulated. Twenty-four of these lncRNAs have not previously been described in colon cancer, 12 of which are upregulated and 12 of which are downregulated (Table 1). Conclusions: This analysis of RNA-seq data from TCGA has identified dysregulated lncRNAs which have not previously been described in human colon cancer. These lncRNAs may have significant roles in colon cancer tumor signaling. Table 1.Differential expression of lncRNA not described in colon cancerlncRNALog Fold ChangeP-valueDescription in other cancersKRT16P14.1041.36E-21Increased in lung squamous cell carcinomaBOK-AS13.7784.98E-09Increased in oral squamous cell carcinomaCELP3.1151.30E-09Not availableCLDN10-AS12.3944.61E-12Not availablePOU6F2-AS12.2678.25E-09Not availableSLC7A11-AS12.1931.60E-13Decreased in gastric adenocarcinomaCSAG42.1083.59E-10Not availableLUCAT12.0224.21E-11Increased in Ovarian cancer, renal clear cell carcinoma, head and neck squamous cell carcinoma, Non-small cell cancer, glioma, osteosarcoma, esophageal squamous cell carcinomaVPS9D1-AS11.9795.27E-21Decreased in gastric adenocarcinoma, Increased in non-small cell lung cancerLEF1-AS11.8464.48E-13Increased in glioblastomaCASC81.6485.64E-06Single nucleotide polymorphisms in colorectal adenocarcinomaLINC004911.5903.11E-04Not availableLINC00648-1.5021.02E-15Not availableLINC00163-1.6751.03E-22Not availableSATB2-AS1-1.8074.18E-09Increased in osteosarcomaLINC00702-2.1424.81E-18Not availableTRHDE-AS1-2.2623.44E-24Not availableLINC00908-2.3082.76E-103Not availableLINC00483-2.4012.87E-39Increased in gastric adenocarcinomaLINC00461-2.4401.42E-41Increased in glioma, multiple myelomaFENDRR-2.6872.12E-58Decreased in breast cancer, prostate cancer, osteosarcoma, gastric adenocarcinoma,ARHGEF26-AS1-2.7148.55E-32Not availableADAMTS9-AS2-2.9041.78E-74Increased in lung cancer salivary adenoid cystic carcinoma, Decreased in glioma, gastric adenocarcinomaMT1JP-4.4601.08E-114Decreased in retinoblastoma, Decreased in gastric adenocarcinoma Citation Format: Stephen J. O'Brien, Theodore Kalbfleisch, Sudhir Srivastava, Shesh Rai, Susan Galandiuk. Differential expression of long non-coding RNA in colon adenocarcinoma RNA-sequence data set [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1817.